Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion

Journal of Psychopharmacology
C NormanG W Bennett

Abstract

Neurotensin (NT) has been proposed as an endogenous antipsychotic based in part on the similarity in behavioural effects to antipsychotic drugs, for example, attenuation of both amphetamine-induced hyperlocomotion (AH) and amphetamine disrupted pre-pulse inhibition in the rat. However, there is some evidence that repeated administration of NT or an analogue produces behavioural tolerance to such effects. The present experiments sought to confirm and extend these findings by testing the effects on AH of 7 days central administration of NT and the NT1 selective analogue PD 149163 and the effects of 21 days central administration of NT. NT and PD149163 continuously administered for 7 days produced no effect on AH (in contrast to attenuation with a single injection here and previously reported), whereas 21 days of NT administration potentiated AH. Together, these studies report that the effects of NT or a NT analogue on AH depends on the duration of administration of peptide. The results are discussed in comparison with the reported antipsychotic properties of acute administration of NT and possible mechanisms involving NT1 receptors.

References

Mar 1, 1976·European Journal of Pharmacology·T Ljungberg, U Ungerstedt
Feb 15, 1979·European Journal of Pharmacology·B V ClineschmidtP B Bunting
Jan 1, 1992·Annals of the New York Academy of Sciences·W RostèneD Pelaprat
Jan 1, 1988·Schizophrenia Research·L H LindströmC Nemeroff
May 7, 1981·Nature·G N ErvinA J Prange
May 10, 1995·Annals of the New York Academy of Sciences·P D LambertC D Kilts
Jun 20, 1997·Brain Research·D FeifelN R Swerdlow
Oct 21, 2000·Journal of Neuroscience Methods·P E HoltomG W Bennett
Aug 30, 2001·European Journal of Pharmacology·M BoulesE Richelson
May 22, 2002·Psychopharmacology·Elisabeth B BinderClinton D Kilts
Mar 20, 2004·Journal of Neurochemistry·Maud LeonettiMarie-Françoise Suaud-Chagny
May 20, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kimberly A PetrieAriel Y Deutch
Dec 16, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Ricardo CácedaCharles B Nemeroff

❮ Previous
Next ❯

Citations

Jan 15, 2011·The Journal of Biological Chemistry·Dominic ThibaultLouis-Éric Trudeau
Dec 7, 2010·The Journal of Pharmacology and Experimental Therapeutics·Paul S FrankelGlen R Hanson
Feb 14, 2014·Psychopharmacology·Mario E AlburgesGlen R Hanson
Feb 26, 2016·Behavioural Brain Research·Chelsea A VadnieDoo-Sup Choi
Jun 15, 2014·Neuropharmacology·Chelsea A VadnieDoo-Sup Choi
May 21, 2013·The Journal of Pharmacology and Experimental Therapeutics·Glen R HansonMario E Alburges

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.